For cardiorenal populations, costs don’t rise gradually. They accelerate at each stage of kidney disease progression. These findings suggest that important opportunities for intervention may exist much earlier in the disease trajectory than traditionally recognized.
A new analysis of 2024 Medicare fee-for-service claims data identifies patients with CKD stage 3a and heart failure as a distinct rising-risk population. Per-member-per-month expenditures run 38 to 269 percent higher than for kidney-only patients and readmission rates reach up to 68 percent higher.
Coordinated, specialist-led care models have shown measurable impact. These findings suggest the interaction between kidney disease and cardiovascular disease may provide a more meaningful lens through which to identify future high-cost populations.
Download the report to learn:
• Why CKD stage 3a + heart failure patients cost 38 to 269 percent more per member
• How specialist-led care models produced a 77.2 percent reduction in kidney disease progression
• What the findings mean for Medicare Advantage plans, ACOs and total-cost-of-care strategies